Dashboard
Manage Tickers

IFRX InflaRx N.V.

Nasdaq inflarx.de


$ 1.39 $ 0.18 (14.75 %)    

Friday, 24-Oct-2025 16:00:10 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 1.4
$ 1.24
$ 1.32 x 230
$ 1.45 x 500
$ 1.22 - $ 1.42
$ 0.71 - $ 2.82
1,084,533
na
82.44M
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

biogens-immunology-pipeline-has-long-term-potential-analyst
Biogen's Immunology Pipeline Has Long-Term...
10/24/2025 16:47:04

Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across mul...

inflarx-regains-nasdaq-compliance
InflaRx Regains Nasdaq Compliance
09/12/2025 12:36:51

InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement s...

top-4-biotech-stocks-set-for-a-breakout-momentum-scores-surge
Top 4 Biotech Stocks Set For A Breakout: M...
09/08/2025 09:59:39

Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Ed...

hc-wainwright--co-assumes-inflarx-at-buy-announces-price-target-of-6
HC Wainwright & Co. Assumes InflaRx at Buy...
09/02/2025 10:49:28

HC Wainwright & Co. analyst Matthew Keller assumes InflaRx (NASDAQ:IFRX) with a Buy rating and announces Price Target of...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
08/29/2025 17:05:57

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
08/28/2025 17:06:35

inflarx-q2-eps-024-misses-017-estimate-sales-44708k-miss-50167k-estimate
InflaRx Q2 EPS $(0.24) Misses $(0.17) Esti...
08/07/2025 11:36:47

InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.17) by ...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

inflarx-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement
InflaRx Receives Nasdaq Deficiency Notice ...
07/11/2025 20:15:48

oppenheimer-maintains-outperform-on-inflarx-lowers-price-target-to-3
Oppenheimer Maintains Outperform on InflaR...
05/29/2025 16:35:56

Oppenheimer analyst Andreas Argyrides maintains InflaRx (NASDAQ:IFRX) with a Outperform and lowers the price target from $6 ...

crude-oil-gains-2-macys-lowers-earnings-forecast
Crude Oil Gains 2%; Macy's Lowers Earnings...
05/28/2025 16:19:22

inflarx-ends-lead-asset-development-after-failed-study-for-rare-and-painful-skin-disease
InflaRx Ends Lead Asset Development After ...
05/28/2025 15:00:12

InflaRx ends its Phase 3 trial of vilobelimab in pyoderma gangrenosum and shifts focus to INF904 amid efforts to extend its cas...

us-stocks-gain-abercrombie--fitch-posts-upbeat-earnings
US Stocks Gain; Abercrombie & Fitch Posts ...
05/28/2025 13:56:36

why-box-shares-are-trading-higher-by-12-here-are-20-stocks-moving-premarket
Why Box Shares Are Trading Higher By 12%; ...
05/28/2025 09:22:42

inflarx-halts-vilobelimab-phase-3-trial-in-pyoderma-gangrenosum-after-futility-finding-in-interim-analysis
InflaRx Halts Vilobelimab Phase 3 Trial In...
05/28/2025 06:36:03

the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelima...

this-centessa-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-top-2-initiations-for-thursday
This Centessa Pharmaceuticals Analyst Begi...
05/08/2025 14:42:35

oppenheimer-initiates-coverage-on-inflarx-with-outperform-rating-announces-price-target-of-6
Oppenheimer Initiates Coverage On InflaRx ...
05/08/2025 14:15:34

Oppenheimer analyst Andreas Argyrides initiates coverage on InflaRx (NASDAQ:IFRX) with a Outperform rating and announces Pri...

inflarx-q1-eps-014-beats-019-estimate
InflaRx Q1 EPS $(0.14) Beats $(0.19) Estimate
05/07/2025 11:36:54

InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.19) by 26...

Core News & Articles
Earnings Scheduled For May 7, 2025
05/07/2025 08:33:08

preview-inflarxs-earnings
Preview: InflaRx's Earnings
05/06/2025 21:01:42

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION